In a filing, Arbutus Biopharma Corp revealed its Director McElhaugh Michael J. acquired Company’s shares for reported $0.8 million on Apr 21 ’25. In the deal valued at $3.26 per share,246,886 shares were bought.
Then, McElhaugh Michael J. bought 53,114 shares, generating $170,098 in total proceeds.
Before that, Sofia Michael J. bought 250,000 shares. Arbutus Biopharma Corp shares valued at $875,000 were divested by the Officer at a price of $3.50 per share.
Jefferies upgraded its Arbutus Biopharma Corp [ABUS] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late February with a ‘”a Hold”‘ rating. H.C. Wainwright began covering ABUS with “Buy” recommendation on December 17, 2020.
Price Performance Review of ABUS
On Tuesday, Arbutus Biopharma Corp [NASDAQ:ABUS] saw its stock jump 1.27% to $3.18. Over the last five days, the stock has gained 2.91%. Arbutus Biopharma Corp shares have risen nearly 0.63% since the year began. Nevertheless, the stocks have fallen -2.75% over the past one year. While a 52-week high of $4.72 was reached on 05/02/25, a 52-week low of $2.70 was recorded on 04/09/25.
Levels Of Support And Resistance For ABUS Stock
The 24-hour chart illustrates a support level at 3.13, which if violated will result in even more drops to 3.07. On the upside, there is a resistance level at 3.23. A further resistance level may holdings at 3.28.
How much short interest is there in Arbutus Biopharma Corp?
A steep rise in short interest was recorded in Arbutus Biopharma Corp stocks on 2025-06-13, growing by 1.34 million shares to a total of 12.84 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 11.5 million shares. There was a rise of 10.41%, which implies that there is a positive sentiment for the stock.
